A FGF2 trap molecule (FP‐1039) has been tested in a clinical trial for patients with malignant solid tumors.[15, 29] Recently, a new anti‐FGF2 monoclonal antibody (mAb), 3F12E7, was used in a B16‐F10 melanoma model and could reduce the number and size of metastatic foci in lungs.[30] We evaluated whether the therapeutic use of an anti‐FGF2 monoclonal antibody (3F12E7) could inhibit LNMAC‐induced lymph node metastasis. This evidence concerns the gene FGF2 and melanoma.